# psoriasis - gemini-3.6-flash

- Benchmark system: E2seq + Agent RAG
- Repeat: 5
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Google Gemini / gemini-3.6-flash
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 44224
- Completion tokens: 32956
- Reasoning tokens: 8347
- Total tokens: 77180
- API requests reported: 3
- Elapsed seconds: 55.805
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1150.303
- Question handoff seconds: 1163.566
- Final benchmark system: E2seq; file rank 3/5; original repeat 5; model vendor: Google Gemini

---
### 1. Overall Biological Interpretation

The differential expression profile comparing psoriatic lesional skin to normal control skin reveals extensive transcriptomic remodeling defined by intense epithelial inflammation, epidermal hyperproliferation, perturbed keratinocyte differentiation, and innate host defense activation. Out of the 100 differentially expressed transcripts analyzed, 90 are significantly upregulated and 10 are downregulated (all FDR $\le 4.50 \times 10^{-61}$). 

The dominant transcriptomic signature is led by extreme fold-change increases in interleukin-36 family cytokines (`IL36A`, `IL36G`), interleukin-20 family cytokines (`IL19`, `IL20`), antimicrobial alarmins and defensins (`DEFB4A`, `DEFB4B`, `S100A7A`, `S100A12`, `S100A8`), cornified envelope structural proteins (`SPRR2A`, `SPRR2B`, `SPRR3`, `LCE3A`), and clade B serine protease inhibitors (`SERPINB3`, `SERPINB4`, `PI3`). Concurrently, downregulated transcripts include specific growth factor signaling components (`BTC` / betacellulin, log2FC = -4.2989) and metabolic/non-coding regulators (`CYP2W1`, `UGT3A2`, `WAKMAR1`). Collectively, these features mirror the canonical pathophysiological triad of plaque psoriasis: feed-forward IL-17/IL-36 cytokine signaling, regenerative epidermal hyperplasia with incomplete terminal differentiation (parakeratosis), and heavy neutrophil/leukocyte chemoattraction into the skin tissue.

---

### 2. Core Biological Programs

```
+-------------------------------------------------------------------------------------------------------------------------+
|                                               CORE BIOLOGICAL PROGRAMS                                                  |
+------------------------------------+-----------+-----------------------------------+------------------------------------+
| Program Name                       | Direction | Representative Genes              | Canonical Pathway Reference        |
+------------------------------------+-----------+-----------------------------------+------------------------------------+
| 1. IL-36 & IL-17 Driven Cytokine   | Upregul.  | IL36A, IL36G, IL36RN, IL19, IL20, | KEGG: IL-17 signaling pathway /    |
|    & Chemokine Signaling           |           | IL26, CXCL13, CXCR2, TNIP3        | Cytokine-cytokine receptor network |
| 2. Epidermal Differentiation &     | Upregul.  | SPRR2A, SPRR2B, SPRR2D, SPRR3,    | Reactome: Formation of the         |
|    Cornified Envelope Assembly     |           | LCE3A, LCE3D, KRT6A, GJB2, GJB6   | cornified envelope (R-HSA-6809371) |
| 3. Antimicrobial Peptides &        | Upregul.  | DEFB4A, DEFB4B, DEFB103A/B,       | GO: Antimicrobial Humoral Response |
|    Innate Host Defense             |           | S100A7, S100A7A, S100A8, S100A12  | (GO:0019730)                       |
| 4. Serine Protease Inhibition &    | Upregul.  | SERPINB3, SERPINB4, SERPINB11/13, | GO: Serine-type endopeptidase      |
|    Cutaneous Barrier Homeostasis   |           | PI3, TMPRSS11D, PRSS27, KLK13     | inhibitor activity (GO:0004867)    |
| 5. Epidermal Lipid & Xenobiotic    | Mixed     | Up: AKR1B10, AKR1B15, FABP5,      | KEGG: Arachidonic acid &           |
|    Metabolic Reprogramming         |           | PLA2G4D, KYNU; Down: CYP2W1, BTC  | xenobiotic metabolism              |
+------------------------------------+-----------+-----------------------------------+------------------------------------+
```

#### Program 1: IL-36 and IL-17 Driven Pro-inflammatory Cytokine & Chemokine Signaling
* **Direction:** Upregulated
* **Major Supporting Genes:** `IL36A` (log2FC = 11.3736, FDR = $1.65 \times 10^{-98}$), `IL36G` (log2FC = 5.6841, FDR = $1.43 \times 10^{-90}$), `IL36RN` (log2FC = 3.0052, FDR = $3.85 \times 10^{-62}$), `IL19` (log2FC = 7.5795, FDR = $9.04 \times 10^{-84}$), `IL20` (log2FC = 5.6674, FDR = $2.85 \times 10^{-71}$), `IL26` (log2FC = 4.3612, FDR = $3.79 \times 10^{-65}$), `CXCL13` (log2FC = 5.8934, FDR = $9.69 \times 10^{-68}$), `CXCR2` (log2FC = 2.7006, FDR = $9.08 \times 10^{-64}$), `TNIP3` (log2FC = 7.2788, FDR = $2.82 \times 10^{-83}$), `ZC3H12A` (log2FC = 3.8483, FDR = $2.49 \times 10^{-71}$).
* **Standardized Pathway:** KEGG: IL-17 signaling pathway / Cytokine-cytokine receptor interaction (GO:0032496 Response to lipopolysaccharide).
* **Biological Rationale:** Epidermal keratinocytes and infiltrating immune cells produce pro-inflammatory IL-1 family cytokines (`IL36A`, `IL36G`) and IL-20 family cytokines (`IL19`, `IL20`, `IL26`). These factors act in autocrine/paracrine loops to activate NF-$\kappa$B and STAT3 signaling, promoting inflammatory cell recruitment (`CXCL13`, `CXCR2`). Upregulation of negative feedback regulators (`IL36RN`, `TNIP3`, `ZC3H12A`) reflects an endogenous, albeit insufficient, counter-regulatory effort to restrain persistent inflammation.
* **Evidence Strength & Limitations:** Strong internal statistical significance and high effect sizes across multiple canonical cytokines. However, bulk RNA sequencing cannot resolve whether cytokine transcription translates to functional protein secretion or local receptor saturation within specific cell layers.

#### Program 2: Epidermal Differentiation & Cornified Envelope Formation
* **Direction:** Upregulated
* **Major Supporting Genes:** `SPRR2A` (log2FC = 7.3121, FDR = $2.93 \times 10^{-85}$), `SPRR2B` (log2FC = 6.3799, FDR = $4.03 \times 10^{-79}$), `SPRR2D` (log2FC = 5.9201, FDR = $8.03 \times 10^{-77}$), `SPRR3` (log2FC = 7.1798, FDR = $1.80 \times 10^{-70}$), `LCE3A` (log2FC = 8.2976, FDR = $1.42 \times 10^{-64}$), `LCE3D` (log2FC = 5.3141, FDR = $1.82 \times 10^{-63}$), `KRT6A` (log2FC = 4.3026, FDR = $9.86 \times 10^{-68}$), `GJB2` (log2FC = 4.4195, FDR = $1.74 \times 10^{-86}$), `GJB6` (log2FC = 3.0184, FDR = $1.64 \times 10^{-69}$).
* **Standardized Pathway:** Reactome: Formation of the cornified envelope (R-HSA-6809371); GO: Epidermis Development (GO:0008544).
* **Biological Rationale:** The small proline-rich protein (SPRR) family and late cornified envelope (LCE) protein family form essential transglutaminase-crosslinked structural scaffolds during epidermal maturation. Their massive co-induction, alongside stress keratins (`KRT6A`) and intercellular gap junction channels (`GJB2`, `GJB6`), signifies severe regenerative epidermal hyperplasia and abnormal cornified envelope assembly.
* **Evidence Strength & Limitations:** High multigene convergence across structural gene clusters. A key limitation is that transcript abundance alone does not distinguish between functional cross-linked envelope assembly versus parakeratotic stratum corneum barrier disruption.

#### Program 3: Antimicrobial Peptides & Innate Host Defense
* **Direction:** Upregulated
* **Major Supporting Genes:** `DEFB4A` (log2FC = 11.1829, FDR = $2.18 \times 10^{-69}$), `DEFB4B` (log2FC = 11.0308, FDR = $3.70 \times 10^{-71}$), `DEFB103A` (log2FC = 5.7580, FDR = $5.76 \times 10^{-68}$), `DEFB103B` (log2FC = 5.7514, FDR = $1.86 \times 10^{-68}$), `S100A7` (log2FC = 7.0948, FDR = $3.49 \times 10^{-62}$), `S100A7A` (log2FC = 9.8327, FDR = $9.25 \times 10^{-63}$), `S100A8` (log2FC = 7.7294, FDR = $6.05 \times 10^{-66}$), `S100A12` (log2FC = 8.3288, FDR = $7.94 \times 10^{-97}$), `VNN3P` (log2FC = 8.2833, FDR = $2.63 \times 10^{-146}$).
* **Standardized Pathway:** GO: Antimicrobial Humoral Response (GO:0019730) / KEGG: Staphylococcus aureus infection.
* **Biological Rationale:** Human beta-defensins (`DEFB4A`, `DEFB4B`, `DEFB103A/B`) and S100 calcium-binding alarmins (`S100A7`, `S100A8`, `S100A12`) act as endogenous microbicides and potent chemoattractants for leukocytes. Their extreme elevation protects psoriatic plaques against secondary bacterial infections while continuously driving immune cell infiltration.
* **Evidence Strength & Limitations:** Unambiguous, highly significant upregulation across independent alarmin families. Genomic copy number variations (e.g., at the `DEFB4A`/`DEFB4B` locus) can complicate RNA alignment and exact fold-change estimation.

#### Program 4: Serine Protease Inhibition & Cutaneous Barrier Homeostasis
* **Direction:** Upregulated
* **Major Supporting Genes:** `SERPINB3` (log2FC = 6.7419, FDR = $1.36 \times 10^{-77}$), `SERPINB4` (log2FC = 9.1181, FDR = $6.68 \times 10^{-66}$), `SERPINB11` (log2FC = 4.4680, FDR = $1.08 \times 10^{-61}$), `SERPINB13` (log2FC = 3.0949, FDR = $4.09 \times 10^{-67}$), `PI3` (log2FC = 9.2404, FDR = $1.53 \times 10^{-69}$), `TMPRSS11D` (log2FC = 7.7490, FDR = $1.49 \times 10^{-82}$), `PRSS27` (log2FC = 4.2448, FDR = $1.62 \times 10^{-62}$), `KLK13` (log2FC = 4.0521, FDR = $2.78 \times 10^{-70}$).
* **Standardized Pathway:** GO: Serine-type endopeptidase inhibitor activity (GO:0004867) / Reactome: Regulation of Proteolysis.
* **Biological Rationale:** Serine proteases (`TMPRSS11D`, `PRSS27`, `KLK13`) mediate epidermal desquamation and pro-inflammatory signaling. In response, keratinocytes induce clade B serpins (`SERPINB3`, `SERPINB4`) and peptidase inhibitor 3 (`PI3` / elafin) to block intracellular lysosomal damage and extracellular protease activity.
* **Evidence Strength & Limitations:** Consistent co-upregulation of enzymes and their physiological inhibitors. Direct enzymatic activity assays are needed to confirm the net proteolytic balance.

#### Program 5: Epidermal Lipid & Xenobiotic / Metabolic Reprogramming
* **Direction:** Mixed (Predominantly Upregulated, selective downregulation)
* **Major Supporting Genes:** Upregulated: `AKR1B10` (log2FC = 6.2654, FDR = $2.35 \times 10^{-89}$), `AKR1B15` (log2FC = 5.2311, FDR = $2.35 \times 10^{-89}$), `FABP5` (log2FC = 3.6446, FDR = $2.76 \times 10^{-81}$), `PLA2G4D` (log2FC = 4.6148, FDR = $2.08 \times 10^{-79}$), `PLA2G4E` (log2FC = 2.4699, FDR = $3.25 \times 10^{-65}$), `KYNU` (log2FC = 4.4158, FDR = $2.00 \times 10^{-91}$); Downregulated: `CYP2W1` (log2FC = -4.7044, FDR = $7.87 \times 10^{-68}$), `UGT3A2` (log2FC = -4.5908, FDR = $2.22 \times 10^{-63}$), `BTC` (log2FC = -4.2989, FDR = $1.78 \times 10^{-73}$).
* **Standardized Pathway:** KEGG: Arachidonic acid metabolism / Xenobiotic metabolism / Tryptophan metabolism.
* **Biological Rationale:** Psoriatic keratinocytes shift metabolic priorities toward lipid mediator synthesis (`PLA2G4D`, `FABP5`), aldehyde detoxification (`AKR1B10`), and immunosuppressive tryptophan catabolism (`KYNU`). Simultaneous suppression of cytochrome P450 enzymes (`CYP2W1`), glucuronosyltransferases (`UGT3A2`), and physiological EGFR ligands (`BTC`) reflects perturbed baseline epidermal metabolism.
* **Evidence Strength & Limitations:** Clear shifts across metabolic enzyme classes; however, metabolomic and lipidomic flux studies are required to confirm pathway activity.

---

### 3. Key Genes and Interaction Modules

1. **`IL36A` & `IL36G` Module**
   * **Dataset Evidence:** Highly upregulated (`IL36A` log2FC = 11.3736; `IL36G` log2FC = 5.6841).
   * **Role:** Master upstream pro-inflammatory cytokines triggering keratinocyte activation.
   * **Relationship Nature:** *Pathway co-membership & direct physical interaction* with the shared heterodimeric receptor complex (`IL1RL2` / `IL1RAP`) based on Reactome and STRING records.

2. **`DEFB4A` & `DEFB4B` Module**
   * **Dataset Evidence:** Highly upregulated (`DEFB4A` log2FC = 11.1829; `DEFB4B` log2FC = 11.0308).
   * **Role:** Key antimicrobial peptide effector downstream of IL-17 and IL-36 signaling.
   * **Relationship Nature:** *Co-expression & paralogous genomic co-membership*; both share *pathway co-membership* in chemoattracting CCR6-expressing immune cells.

3. **`S100A7`, `S100A8`, & `S100A12` Module**
   * **Dataset Evidence:** Strongly upregulated (`S100A7` log2FC = 7.0948; `S100A8` log2FC = 7.7294; `S100A12` log2FC = 8.3288).
   * **Role:** Cutaneous alarmins modulating calcium signaling, neutrophil chemotaxis, and innate immunity.
   * **Relationship Nature:** *Co-expression & direct physical interaction* (S100A8 forms heterodimers with S100A9; STRING interaction score > 0.90) and *pathway co-membership* in neutrophil activation.

4. **`SERPINB3` & `SERPINB4` Module**
   * **Dataset Evidence:** Strongly upregulated (`SERPINB3` log2FC = 6.7419; `SERPINB4` log2FC = 9.1181).
   * **Role:** Endogenous serpins protecting hyperproliferative keratinocytes against proteolysis and apoptosis.
   * **Relationship Nature:** *Co-expression & direct physical interaction* with target lysosomal cysteine and serine proteases (e.g., Cathepsin G / CTSG per STRING records).

5. **`SPRR2A` / `SPRR2B` / `SPRR2D` / `SPRR3` Module**
   * **Dataset Evidence:** Highly co-upregulated (log2FC ranging from 5.9201 to 7.3121).
   * **Role:** Structural precursors for transglutaminase cross-linking in hyperkeratotic epidermis.
   * **Relationship Nature:** *Co-expression & pathway co-membership* within the Reactome cornified envelope assembly pathway (R-HSA-6809371).

6. **`IL19` & `IL20` Module**
   * **Dataset Evidence:** Strongly upregulated (`IL19` log2FC = 7.5795; `IL20` log2FC = 5.6674).
   * **Role:** Paracrine drivers of keratinocyte acanthosis and STAT3 activation.
   * **Relationship Nature:** *Co-expression & pathway co-membership* in IL-20 family signaling through the IL-20R1/IL-20R2 receptor complex.

7. **`AKR1B10` & `FABP5` Module**
   * **Dataset Evidence:** Upregulated (`AKR1B10` log2FC = 6.2654; `FABP5` log2FC = 3.6446).
   * **Role:** Enzymatic control of retinoic acid lipid signaling and fatty acid transport in skin.
   * **Relationship Nature:** *Co-expression & metabolic pathway co-membership* in epidermal lipid uptake and retinoic acid synthesis.

8. **`KYNU`**
   * **Dataset Evidence:** Upregulated (`KYNU` log2FC = 4.4158, FDR = $2.00 \times 10^{-91}$).
   * **Role:** Kynureninase enzyme diverting tryptophan into kynurenine metabolites, modulating local T-cell responses.
   * **Relationship Nature:** *Co-expression & functional pathway co-membership* with inflammatory cytokine pathways.

9. **`BTC` (Betacellulin)**
   * **Dataset Evidence:** Downregulated (`BTC` log2FC = -4.2989, FDR = $1.78 \times 10^{-73}$).
   * **Role:** Physiological EGFR ligand whose loss reflects disrupted normal basal epidermal homeostatic signaling.
   * **Relationship Nature:** *Regulatory interaction & pathway co-membership* within the ERBB/EGFR signaling cascade.

10. **`CD274` (PD-L1) & `CXCL13` Module**
    * **Dataset Evidence:** Upregulated (`CD274` log2FC = 3.4395; `CXCL13` log2FC = 5.8934).
    * **Role:** Immuno-inhibitory checkpoint ligand (`CD274`) and lymphoid chemoattractant (`CXCL13`) governing inflammatory cell infiltration.
    * **Relationship Nature:** *Indirect functional co-expression*, reflecting immune cell recruitment and secondary feedback suppression within lesional tissue.

---

### 4. Validation Priorities

#### 1. Mechanistic Hypothesis: Feed-Forward IL-36 / IL-17 Amplification Loop in Keratinocytes
* **Classification:** Mechanistic hypothesis
* **Prioritization Rationale:** `IL36A` displays one of the highest fold changes in the dataset (log2FC = 11.3736), driving secondary antimicrobial and structural gene cascades.
* **Current Dataset Evidence:** Co-induction of `IL36A`, `IL36G`, `IL36RN`, `IL19`, `IL20`, `DEFB4A`, and `DEFB4B`.
* **External Evidence:** Functional studies and Reactome records demonstrate IL-36 receptor binding triggers NF-$\kappa$B/MAPK cascades, promoting defensin expression in psoriasis models. Note: *External statistical validation in an independent cohort was not performed in this study.*
* **Next Step for Validation:** Reconstituted 3D human epidermis models exposed to recombinant IL-36/IL-17, followed by siRNA knockdown or receptor antagonists to measure downstream target gene and protein levels.
* **Conclusion Status:** Supported hypothesis.

#### 2. Therapeutic Target: Neutralization of IL-20 Family Cytokines (`IL19` / `IL20`)
* **Classification:** Therapeutic target
* **Prioritization Rationale:** `IL19` (log2FC = 7.5795) and `IL20` (log2FC = 5.6674) specifically stimulate keratinocyte acanthosis and STAT3 phosphorylation.
* **Current Dataset Evidence:** Robust statistical co-upregulation of `IL19` and `IL20` in lesional skin tissue.
* **External Evidence:** OpenTargets and clinical trial databases document therapeutic targeting of IL-20 signaling. However, drug target existence alone does not prove therapeutic efficacy in plaque psoriasis without independent clinical trial results.
* **Next Step for Validation:** Monoclonal antibody neutralizing assays in ex vivo psoriatic skin explants to evaluate reduction in epidermal thickness and reduction of hyperproliferation markers (`KRT6A`).
* **Conclusion Status:** Supported hypothesis.

#### 3. Biomarker: Non-Invasive Stratum Corneum Antimicrobial Peptide Panel (`DEFB4A/B`, `S100A12`, `PI3`)
* **Classification:** Biomarker
* **Prioritization Rationale:** These transcripts exhibit extreme fold-change increases (log2FC 8.33 to 11.18) and encode highly stable secreted proteins.
* **Current Dataset Evidence:** `DEFB4A` (log2FC = 11.1829), `DEFB4B` (log2FC = 11.0308), `PI3` (log2FC = 9.2404), `S100A12` (log2FC = 8.3288).
* **External Evidence:** S100 proteins and Elafin (PI3) are established in literature as skin tissue markers correlating with psoriasis area and severity index (PASI).
* **Next Step for Validation:** Enzyme-linked immunosorbent assay (ELISA) or targeted LC-MS/MS quantification on skin tape-stripping samples from psoriasis patients before and after biologic therapy.
* **Conclusion Status:** Supported hypothesis.

#### 4. Interaction / Network Hypothesis: Protective Serine Protease Inhibitor Network (`SERPINB3/4`, `PI3`)
* **Classification:** Interaction / network hypothesis
* **Prioritization Rationale:** Concurrent upregulation of serine proteases (`TMPRSS11D`, `PRSS27`) and antiproteases suggests an active endogenous tissue-protective network.
* **Current Dataset Evidence:** Co-upregulation of `SERPINB3` (log2FC = 6.7419), `SERPINB4` (log2FC = 9.1181), and `PI3` (log2FC = 9.2404).
* **External Evidence:** STRING and IntAct document physical binding between SERPINB proteins and target cathepsins/proteases.
* **Next Step for Validation:** Protease activity assays using fluorogenic substrate cleavage in keratinocyte lysates overexpressing or lacking `SERPINB3/SERPINB4`.
* **Conclusion Status:** Exploratory hypothesis.

#### 5. Confounding / Composition Check: Single-Cell Resolution of Epidermal vs. Immune Infiltrate Signals
* **Classification:** Confounding or composition check
* **Prioritization Rationale:** Bulk lesional skin biopsies merge transcriptomic signals from hyperplastic keratinocytes, T cells, dendritic cells, and neutrophils.
* **Current Dataset Evidence:** Simultaneous upregulation of keratinocyte markers (`KRT6A`, `SPRR2A`), neutrophil chemoattractants/receptors (`CXCR2`, `S100A8`), and immune regulators (`CD274`, `CXCL13`).
* **External Evidence:** Single-cell RNA-seq datasets (e.g., HPA cell-type records) demonstrate that `IL36G` and `DEFB4A` are keratinocyte-derived, whereas `CXCL13` originates from infiltrating immune cells.
* **Next Step for Validation:** Computational deconvolution (e.g., CIBERSORTx) or single-cell/spatial RNA sequencing on paired lesional vs. non-lesional skin biopsies.
* **Conclusion Status:** Exploratory hypothesis.

---

### 5. Evidence Grounding

```
+-------------------------------------------------------------------------------------------------------------------------+
|                                               EVIDENCE GROUNDING SUMMARY                                                |
+------------------------------+----------------------------------+-------------------------------------------------------+
| Category                     | Evidence Sources                 | Direct Findings & Contextual Evidence                 |
+------------------------------+----------------------------------+-------------------------------------------------------+
| Direct Input Dataset         | Differential Expression Ledger   | 100 unique genes with exact log2FC (ranging from      |
|                              |                                  | -6.25 to +11.37) and FDR values (all <= 4.50e-61).    |
| Pathway / Ontology           | Reactome, QuickGO, KEGG          | Enriched in IL-17 signaling, epidermis development    |
|                              |                                  | (GO:0008544), & cornified envelope (R-HSA-6809371).   |
| Protein / Regulatory Network | STRING, TRRUST, IntAct           | Interlocking physical/functional nodes (IL36-IL1RAP,  |
|                              |                                  | S100A8 heterodimers, SPRR cross-linking modules).     |
| Disease & Clinical           | GWAS, OpenTargets, ClinVar       | GWAS loci and ClinVar loss-of-function variants in    |
|                              |                                  | IL36RN linked to generalized pustular psoriasis.      |
| Tissue / Cell Expression     | GTEx, Human Protein Atlas (HPA)  | Skin-enriched baseline expression for keratinocyte    |
|                              |                                  | structural and antimicrobial genes.                   |
| Drug / Therapeutic           | ChEMBL, ClinicalTrials.gov       | Clinical trials targeting IL-36R (spesolimab) and     |
|                              |                                  | IL-17/IL-23 cytokine axes.                            |
| Published Literature         | PubMed, Europe PMC               | Concordant published literature on IL-36, defensins,  |
|                              |                                  | and S100 proteins in psoriatic lesion pathogenesis.   |
+------------------------------+----------------------------------+-------------------------------------------------------+
```

* **Independent Cohort Validation Status:** *External statistical validation in an independent cohort was not performed in this analysis.* (No external statistical replication metrics, external cohort fold-changes, or external P-values were provided). 
* **Evidence Source Independence & Conflicts:** Databases such as STRING, Reactome, and OpenTargets offer contextual biological plausibility rather than statistical replication. Annotations across these platforms may draw from overlapping primary literature (e.g., shared PubMed citations for IL-36 discovery). No direct evidence conflicts were identified among the primary upregulated cytokine and differentiation pathways.

---

### 6. Limitations and Alternative Explanations

1. **Cell-Composition Confounding (Acanthosis and Leukocyte Infiltration):** Lesional psoriatic skin exhibits dramatic histological changes, including marked thickening of the epidermis (acanthosis) and dense dermal/epidermal inflammatory cell infiltration (neutrophils, T cells, dendritic cells). Consequently, elevated transcript levels for immune genes (e.g., `CXCR2`, `CXCL13`, `CD274`) may reflect an increased proportion of infiltrating leukocytes within the biopsy mass rather than elevated transcription per individual cell. Single-cell RNA sequencing or spatial transcriptomics is required to distinguish cell-type shifts from transcriptional induction.

2. **Absence of Independent Cohort Statistical Validation:** Because external statistical validation was not performed, the effect sizes (log2FC up to 11.37) and significance values (P $< 10^{-60}$) rely solely on the current input sample. Independent cohort validation across diverse patient demographics is necessary to confirm marker stability and rule out cohort-specific biases.

3. **Nonspecific Cutaneous Injury and Stress Response Enriched Signals:** Highly elevated antimicrobial peptides (`DEFB4A`, `DEFB4B`, `S100A7`) and stress keratins (`KRT6A`) are strongly induced by general epidermal barrier disruption, mechanical wound healing, and infection. These signals represent broad cutaneous alarm responses that are not exclusive to psoriasis.

4. **Transcript-to-Protein Divergence and Proteolytic Processing:** RNA-seq measures steady-state transcript abundance, which does not directly dictate active protein concentrations, post-translational modifications, or extracellular protein secretion. For example, precursor IL-36 cytokines require extracellular proteolytic cleavage by neutrophil elastase or cathepsin G to achieve full agonist activity; transcript levels of `IL36A` or `IL36G` do not confirm cleavage state.

5. **Association vs. Causation Ambiguity in Counter-Regulatory Pathways:** Concurrent upregulation of potent anti-inflammatory regulators (`IL36RN`, `TNIP3`, `ZC3H12A`, `CD274`) represents secondary negative-feedback responses triggered by acute tissue inflammation rather than primary pathogenic drivers. Interpreting these elevated transcripts as disease-causing elements would misrepresent their homeostatic protective function.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=73, external claims checked=0, external mismatches=0, status=passed.

Answer model API: Google Gemini / gemini-3.6-flash

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 91/100 selected items (records returned); cbioportal 91/100 selected items (records returned); chembl 11/100 selected items (partially returned; some queries failed); civic 4/100 selected items (records returned); clinicaltrials 40/100 selected items (records returned); clinvar 90/100 selected items (records returned); ensembl 44/100 selected items (partially returned; some queries failed); europepmc 848 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 83/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 76/100 selected items (records returned); humanbase 100/100 selected items (records returned); intact 79/100 selected items (records returned); mygene 100/100 selected items (records returned); omnipath 36/100 selected items (records returned); opentargets 90/100 selected items (records returned); pubmed 669 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 80/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 2/100 selected items (records returned); hmdb 25/100 selected items (records returned); string 78/100 selected items (records returned); trrust 17/100 selected items (records returned)
